Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Athersys, Inc. (NASDAQ: ATHX).

Full DD Report for ATHX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATHX)

Could Athersys Play A Role In The Progression Of CAR-T Therapy?
Background One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands for T-cell. Currently both Novartis ( NVS ) and Gilead (GILD) have CAR-T therapies approved by the FDA. Axicabtagene (Yescarta) is so...
Source: SeekingAlpha
Date: August, 20 2018 10:19
Recent Analysis Shows Williams Partners, GameStop, Opko Health, Athersys, CSX, and Kratos Defense & Security Solutions Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Williams Partners L.P. (NYSE:WPZ), GameStop Corp. (NYSE:GME), Opko Health...
Source: GlobeNewswire
Date: August, 14 2018 07:30
Athersys, Inc. (ATHX) on Q2 2018 Results - Earnings Call Transcript
Athersys, Inc. (ATHX) Q2 2018 Earnings Conference Call August 7, 2018, 04:30 PM ET Executives Laura Campbell - SVP, Finance William Lehmann - President and COO Analysts Chad Messer - Needham & Company Katherine Xu - William Blair Jason McCarthy - Maxim Group Presen...
Source: SeekingAlpha
Date: August, 07 2018 22:23
Athersys beats by $0.05, beats on revenue
Athersys (NASDAQ: ATHX ): Q2 EPS of $0.05 beats by $0.05 . Revenue of $19.4M beats by $8.12M  vs. $0.67M revenue in 2Q17 Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: August, 07 2018 16:09
Athersys Reports Second Quarter 2018 Results
CLEVELAND, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2018. Highlights of the second quarter of 2018 and recent events include: Announced the completion of an expansion of our collaboration w...
Source: GlobeNewswire
Date: August, 07 2018 16:05
Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
CLEVELAND, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and lead the Company’s transition into commercial manufacturing of MultiStem ® , the ...
Source: GlobeNewswire
Date: August, 03 2018 06:00
Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
Pivotal study has received a Special Protocol Assessment (SPA), Fast Track Designation, and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) CLEVELAND, July 31, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced...
Source: GlobeNewswire
Date: July, 31 2018 06:00
Mesoblast Completes Deal In China For Stem Cell Heart Therapies
Mesoblast Limited ( MESO ) announced yesterday that it had entered into a partnership with China based Tasly Pharmaceutical Group . The deal gives Tasly exclusive rights in China for Mesoblast’s allogeneic mesenchymal precursor cell ((MPC)) product candidate MPC-150-IM for the indica...
Source: SeekingAlpha
Date: July, 18 2018 12:47
Asterias' Ischemic Stroke Indication Has The Potential To Add Solid Value To OPC1 Program
Introduction Asterias Biotherapeutics ( AST ) is a stem-cell and allogenic/autologous immune cell-based biotechnology company focused on two rather unrelated indications with high market penetration potential. For an in-depth look at AST in its entirety, please refer to our first article . ...
Source: SeekingAlpha
Date: July, 16 2018 17:15
Biotechnology Companies Involved in Regenerative Medicine
HENDERSON, NV / ACCESSWIRE / July 12, 2018 / The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. With that being said this market could bring incredible value to shareholders of regenerative medici...
Source: ACCESSWIRE IA
Date: July, 12 2018 10:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-111.982.092.091.96790,949
2018-12-101.941.972.041.91808,078
2018-12-071.871.85991.911.82360,367
2018-12-061.841.871.901.84335,798
2018-12-051.951.871.96921.84480,336

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1172,812227,71931.9745Cover
2018-12-1088,687298,66529.6945Cover
2018-12-0746,380114,81440.3958Short
2018-12-0625,413142,48717.8353Cover
2018-12-0447,678141,29133.7445Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATHX.


About Athersys, Inc. (NASDAQ: ATHX)

Logo for Athersys, Inc. (NASDAQ: ATHX)

Not available

 

Contact Information

 

 

Current Management

  • Gil Van Bokkelen / CEO
  • Gil Van Bokkelen /

Current Share Structure

  • Market Cap: $278,085,032 - 05/14/2018
  • Issue and Outstanding: 125,830,331 - 03/07/2018

 


Recent Filings from (NASDAQ: ATHX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ATHX)

Daily Technical Chart for (NASDAQ: ATHX)


Stay tuned for daily updates and more on (NASDAQ: ATHX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ATHX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATHX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATHX and does not buy, sell, or trade any shares of ATHX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/